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Abstract
Background. Renal amyloidosis results from protein mis-
folding and leads to progressive renal insufficiency. Few
data are available concerning the relevance of the histomor-
phological patterns and the dynamics of the disease process.
Methods. Cases of renal amyloidosis in native kidney biop-
sies (n ¼ 203) were retrospectively evaluated for the pattern
of amyloid distribution, the extent of glomerular amyloid
deposition and the amount of interstitial fibrosis and tubular
atrophy. One hundred and fifty-eight cases were character-
ized by immunohistochemistry to determine the biochemical
amyloid type. Morphological findings were correlated with
available clinical data.
Results. According to the predominant site of amyloid dep-
osition, 84.6% showed a glomerular, 9.4% a vascular and
6% a tubulointerstitial distribution pattern. Within the glo-
meruli, amyloid was initially deposited in a focal segmental
fashion that became diffuse and global in later stages. Most
cases were identified as AL lambda (84/158) or AA (68/
158). There was no correlation between the biochemical type
and the distribution pattern. Serum creatinine correlated well
with interstitial fibrosis and tubular atrophy and proteinuria
with the glomerular amyloid load.
Conclusions. The relevance of the different distribution
patterns is unclear at the moment, but they may be due to
the physicochemical properties of the amyloid fibrils in a
given patient. This may become important in future anti-
fibrillar therapies.
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Introduction
Renal amyloidosis is a well-known and well-described dis-
ease, and in most cases a straightforward diagnosis for
renal pathologists evaluating the kidney biopsy. The use
of special stains (i.e. Congo red with polarized light or
fluorescence) establishes the diagnosis without doubt. Its
pathology is determined by the extracellular deposition of
amyloid fibrils that assemble from instable precursor
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proteins. Biochemical typing, usually performed by immu-
nohistochemistry, establishes the biochemical type that is
currently considered the key information provided by the
pathologists because it determines clinical management
and therapy [1–3]. In most published series from the West-
ern world, AL amyloidosis comprises the majority of cases
followed by AA amyloidosis. All other forms are only
infrequently found [3, 4].
Renal amyloidosis shows a number of different distribu-
tion patterns within the kidney compartments. Although
this has been described in a number of case reports and
some biopsy series, these patterns have only been insuffi-
ciently characterized [5–9]. The reason for the preferential
localization to one or the other compartment is not well
established. It seems very likely that the varying chemico-
physical properties of the amyloid fibrils determine the
tropism. These result from the biochemical type, amino
acid sequence and proteolytic fragmentation of the precur-
sor proteins and/or the fibrils [1, 10–12]. Currently, the
distribution patterns do not aid in the management of the
patients. A number of new therapies are being developed
for amyloidosis therapy. These target the formation or
stability of the fibrils or aim to stabilize the precursor
proteins [1].
In our study, we aimed to better describe the amyloid
distribution patterns in a large series of kidney biopsies and
to identify morphological parameters that may be useful for
patient management, especially in the context of the emerg-
ing anti-fibrillar therapies.
Materials and methods
Study design, patients and material
Two hundred and three cases of renal amyloidosis diagnosed in native kidney
biopsies between 1960 and 2007 at the Institute of Pathology were retrieved
from the archives and the clinical data provided at the time of biopsy were
evaluated. The study was approved by the local ethical committee.
For each patient, the following data given at the time of biopsy were
recorded: age, sex, basic disease, serum creatinine and proteinuria. Most of
the patients included in this study (n ¼ 152) were part of a recent study on
the biochemical typing of renal amyloidosis [3].
Histology
Paraffin sections stained with Periodic acid-Schiff (PAS), hemotoxylin and
eosin, trichrome, methenamine silver and Congo red were reevaluated. In all
cases, the number of glomeruli, obsolescent glomeruli, obsolescent glomer-
uli due to amyloid and glomerular crescents were counted. Sections were
systematically evaluated for the presence of amyloid in the glomeruli, pre-
glomerular arterioles, interlobular arteries, vasa recta, tubular basement
membranes and interstitium. The glomerular amyloid load was scored as
segmental (involving<50% of a glomerular cross section) or global (50%
of a glomerular cross section), the latter as mild/moderate or severe in the
most severely affected glomerulus. The amount of interstitial fibrosis was
estimated as area% of the renal cortex. The amount of interstitial inflamma-
tion was scored semiquantitatively (0 ¼ none, 1 ¼ minimal, 2 ¼ mild,
3 ¼ moderate and 4 ¼ severe).
The biochemical type of amyloid has been determined by immuno-
histochemistry in all biopsies received since 1988 (n ¼ 158). The amy-
loid-specific antibodies used in this study were a generous gift of Prof.
R. Linke (Martinsried, Germany). Antibodies against AA, AL-lambda,
AL-kappa and ATTR (transthyretin) were routinely employed on paraf-
fin sections using pretreatment and the ABC method as specified by
Prof. Linke [2].
Transmission electron microscopy was performed in most cases ac-
cording to the standard procedures.
Statistical analysis
Differences between multiple groups were compared using the Kruskal–
Wallis test and followed by a Mann–Whitney U-test to compare two
groups with each other. Nonparametric correlation tests (Spearman’s)
were used where appropriate. All statistics were performed using Graph-
Pad Prism version 5.01 (GraphPad Software, San Diego, CA).
Results
Patient characteristics
The age range of the patients studied was 6.7–87.2 years
with a median of 59.5 years. The male to female ratio was
1.23:1. The median age of patients presenting with AA amy-
loidosis was slightly younger than that of the patients with
AL amyloidosis [median 59.3 years (range 6.7–86.2) versus
64 years (range 41–84); P < 0.01]. AL amyloidosis was rare
before the age of 50 (7/84 patients) and there was no case
before the age of 40. There were no age or sex differences in
regard to the amyloid distribution within the kidneys.
Of the 68 patients diagnosed immunohistochemically
with AA-type amyloidosis, 29 (42.6%) had a clinically
history of chronic (autoimmune) inflammatory disease, 8
(11.8%) of chronic infection, 5 (7.4%) of familial Mediter-
ranean fever and 4 patients had a known malignancy
(Table 1). No information was available in the other cases.
Interestingly, five of the patients in the AA group also had a
monoclonal gammopathy. In addition, there was one patient
showing both AA and AL amyloid, who had a history of
both chronic polyarthritis and monoclonal IgG.
In most of the 84 patients diagnosed with AL-type amy-
loidosis, no clinical history of lymphoma or monoclonal
gammopathy was given. Twenty-four patients (28.6%) had
plasma cell myeloma or another lymphoma and 14 (16.7%)
had a known monoclonal gammopathy with a clinical diag-
nosis of monoclonal gammopathy of unknown significance.
Table 1. Known primary diseases provided at the time of kidney biopsy
for AA and AL amyloidosis
AA amyloidosis
Chronic (autoimmune) inflammatory
disease
29/68 42.6%
Rheumatoid arthritis 15/68
Ankylosing spondylitis 4/68
Inflammatory bowel disease 5/68
Othersa 5/68
Chronic infections 8/68 11.8%
Familial Mediterranean fever 5/68 7.4%
Known malignancyb 4/68 5.9%
No information provided 22/68 32.4%
AL amyloidosis
Plasma cell myeloma 22/84 26.2%
Other B-cell non-Hodgkin lymphoma 2/84 2.4%
Paraproteinemia or paraproteinuria 14/84 16.7%
Solid malignanciesc 1/84 1.2%
Primary myelofibrosis 1/84 1.2%
No information provided 41/84 48.8%
aPsoriasis (two patients), systemic lupus erythematodes, polymyalgia
rheumatica and unclassified chronic autoimmune disease.
bPlasma cell myeloma (two patients), Morbus Waldenstrom and endome-
trial carcinoma.
cColon cancer.
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Twenty-three patients in our study were <40 years at the
time of renal biopsy. Immunohistochemical typing was
performed in 14 cases. All were of the AA type (for further
details see Table 2).
Biochemical type of amyloid
Immunohistochemical typing of amyloid was routinely
performed in all biopsies since 1988 (n ¼ 158; Figure 1A–
D). Eighty-four cases (53.2%) were classified as AL, the
majority [74 (88.1%)] being AL lambda. There were 10
cases with AL kappa. AA-type amyloidosis was found in
68 cases (43%). One case was both positive for AA and
AL lambda. Only one case was identified as ATTR (trans-
thyretin). Four cases were unclassifiable with the antibody
panel employed (2.5%). There was insufficient biopsy mate-
rial to perform immunohistochemistry for additional amyloid
types in three of four cases. The remaining case was also
negative for AFib, AApoA1 and ALysozyme, as well as IgA,
IgG and IgM.
Distribution of amyloid
The majority of cases (170; 84.6%) had dominant glomerular
amyloid deposition (glomerular type; Figure 1E and F). In 19
cases (9.4%), amyloid was found primarily in the arteries and
arterioles (vascular type; Figure 1G) and in 15 cases (6%), the
amyloid was mainly seen in the interstitium (interstitial type;
Figure 1H). Although all cases showed dominant deposition
of amyloid in one of the compartments, amyloid deposition in
most cases was not limited to this compartment (see below).
Glomerular pattern and dynamics of glomerular amyloid
deposition
In the glomerular type, amyloid deposits were domi-
nantly located in the glomeruli in a focal segmental, diffuse
segmental or diffuse global fashion. In most cases, there was
mesangial involvement and in later stages (see below) also
involvement of the peripheral capillaries (Figure 2). Due to
the large number of cases, the dynamics of glomerular amy-
loid deposition could be investigated. The dynamics can be
deducted from both the amyloid amount and distribution
within a single glomerulus, the number of glomeruli in-
volved and the presence of amyloid in the other compart-
ments. Amyloid deposition began in a focal and segmental
fashion and was involving the mesangium first (Stage I,
Figure 3). As the disease progressed, the amount of glomer-
ular amyloid increased and there was also deposition along
the peripheral capillaries. It was first distributed in a diffuse
segmental (Stage II) and then in a diffuse global fashion
(Stage III). In the early global phase, there was a mild-to-
moderate widening of the mesangium and the glomerular
capillaries were still easily recognizable (Stage IIIa). The late
global phase was characterized by severe mesangial as well
as peripheral amyloid deposits and the number of cells
within the lesions decreased. The peripheral capillaries
became narrow and were less well recognizable (Stage IIIb).
Finally, the glomeruli became obsolescent.
Additional, less conspicuous amyloid deposits in the
arterioles were present in 50% of cases with focal segmen-
tal glomerular amyloid deposits (Figure 3; Stage I),
whereas involvement of arteries and the interstitium was
only present in 4.5 and 13.8%, respectively. Once the
glomerular involvement was diffuse (Stage II), the major-
ity of cases had arteriolar involvement (87.8%) and the
number of cases with additional arterial and/or interstitial
involvement increased. With diffuse and global glomeru-
lar amyloid deposits (Stage III), almost all cases showed
arteriolar involvement and approximately two-thirds had
arterial and/or interstitial involvement. Regarding the in-
terstitial involvement, there was no predictable pattern
determining involvement of tubular basement membranes
or vasa recta.
Besides this common pattern of amyloid distribution,
there were five cases with a diffuse nodular pattern and
four cases with an evenly minimal diffuse and global amy-
loid distribution within the mesangium (Figure 1I and J).
Focal crescents were present in four cases, but there were
no other unique findings.
Vascular pattern
In the vascular type, the most obvious amyloid deposits
were seen within arteries or arterioles (Figure 1G). The
distribution could be segmental or circular, the first being
mostly present in arcuate arteries and the later in interlob-
ular arteries and arterioles. Most cases showed involvement
of the outer media, sometimes accompanied by amyloid
deposition in the adjacent interstitium. Few cases had trans-
mural amyloid deposits, sometimes resulting in the forma-
tion of aneurysms (Figure 1K). Once the subendothelial
space was involved, there was a concentric intimal fibrosis
Table 2. Summary of patients <40 years of age at the time of diagnosisa
Age Sex Clinical history
Year of
biopsy
6.7 Female Juvenile rheumatoid arthritis 1994
12.0 Female Familial Mediterranean fever 2005
15.6 Female Cystic fibrosis 1984
17.5 Female Familial Mediterranean fever 2005
19.0 Female Not provided 1996
20.8 Female Familial Mediterranean fever 1988
21.0 Male Chronic autoimmune disease,
unclassified
2003
22.0 Female Rheumatoid arthritis 1993
22.6 Male Osteomyelitis 1964
24.0 Male Ankylosing spondylitis/familial
Mediterranean fever
2004
24.7 Female Colitis ulcerosa 1982
26.2 Female Autoimmune hemolytic anaemia 1981
28.4 Female Not provided 1964
29.0 Female Juvenile rheumatoid arthritis 1984
29.2 Female Not provided 1975
31.0 Male Not provided 2001
31.0 Male Rheumatoid arthritis 2001
32.0 Female Osteomyelitis, abscesses,
HIV infection
2007
33.1 Male Abscesses 1983
34.6 Male Colitis ulcerosa 1994
38.1 Female Tuberculosis 1998
38.3 Male Osteomyelitis 1965
39.0 Male Morbus Crohn 1991
aAll cases typed by immunohistochemistry had AA amyloidosis (patients
presented in italics were not typed by immunohistochemistry).
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without elastosis and subsequent stenosis (Figure 1L) or
even occlusion of the vascular lumina.
All vascular-type cases also showed glomerular amy-
loid deposits. These were very minute in 9/19 cases, be-
coming apparent only by immunohistochemistry. The
other cases showed mild to moderate glomerular involve-
ment. In some cases, there were glomeruli with prominent
amyloid deposits at the vascular pole (Figure 1M). In one
Fig. 1. (A) Biochemical amyloidosis types characterized by immunohistochemistry using amyloid-specific antibodies. (B) Glomerular amyloid deposits of the
AA type (immunohistochemistry, original magnification: 3400). (C) Vascular, glomerular and interstitial amyloid deposits of the AL-type lambda (immu-
nohistochemistry, original magnification: 3200). (D) Interstitial amyloid deposits of the AL-type kappa (immunohistochemistry, original magnification:
3400). (E) Distribution types of renal amyloidosis. (F) Glomerular type with segmental mesangial amyloid deposits (PAS, original magnification: 3400).
(G) Vascular type with prominent amyloid deposits in an interlobular artery without glomerular involvement (PAS, original magnification: 3100). (H)
Interstitial type affecting the medulla (PAS, original magnification: 3100). (I) Glomerulus with nodular amyloid deposits resembling diabetic glomerulo-
sclerosis (PAS, original magnification: 3400). (J) Glomerulus with minimal global mesangial amyloid deposits (Acid Fuchsin Orange G, original magnifi-
cation:3400). (K) Segmental transmural amyloid deposits in an interlobular artery with formation of aneurysms (Elastica van Gieson, original magnification:
3100). (L) Circumferential amyloid deposits in a medium-sized interlobular artery with intimal fibrosis, stenosis and foam cells (Elastica van Gieson, original
magnification: 3400). (M) Prominent amyloid deposits at the vascular pole of a glomerulus (PAS, original magnification: 3400). (N) Giant cell adjacent to
amyloid in the adventitia of a small interlobular artery (PAS, original magnification:3400). (O) Amyloid deposits along the vasa recta and tubular basement
membranes in the medulla (PAS, original magnification: 3400). (P) Focal nodular amyloid deposits in the medulla (PAS, original magnification: 3200).
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case, a giant cell was noted adjacent to vascular amyloid
(Figure 1N).
Interstitial pattern
The interstitial type was characterized by amyloid deposits
surrounding the tubules, usually involving the tubular base-
ment membranes, the peritubular capillaries and/or the vascu-
lar bundles of the vasa recta (Figure 1H and O). Most often, it
was very prominent in the renal medulla and sometimes took a
nodular form (Figure 1P). In most cases, the tubules were well
preserved and did not show signs of tubular atrophy.
Additional involvement of the arterioles was present in
most cases, of the arteries in ~50%. As in the vascular type,
glomerular involvement was minimal in half of the cases
and the remaining showed mild-to-moderate involvement.
Secondary changes in renal amyloidosis
The most frequent and important secondary changes due to
amyloidosis were glomerular obsolescence, interstitial fib-
rosis with tubular atrophy and interstitial inflammation. The
percentage of obsolescent glomeruli due to amyloid depo-
sition increased with the number of glomeruli involved and
a global rather than a segmental involvement (Figure 4A).
Interstitial fibrosis and tubular atrophy also increased with
the amount of amyloid present (Figure 4B). In cases of
either focal or diffuse segmental glomerular involvement,
the extent was small (median 0%). Diffuse and late global
involvement resulted in extensive interstitial fibrosis with tub-
ular atrophy (median 60%, Kruskal–Wallis test: P < 0.0001).
Interstitial inflammation in most cases was minimal and char-
acterized by a lymphohistiocytic cellular infiltrate. Plasma
cells, neutrophilic and eosinophilic granulocytes were not
present. Other rare secondary changes noted were tubular or
interstitial foam cells in 3% of the cases and giant cells ad-
jacent to amyloid deposits in 2.5% of the cases.
Correlations between biochemical type, distribution
patterns, secondary changes and clinical parameters
There was no correlation between the biochemical type of
amyloid and amyloid distribution within the kidney
(Figure 4C). However, AL amyloidosis was more often de-
tected at an earlier stage than AA amyloidosis. One differ-
ence noted in the glomerular type was that AL amyloid was
frequently present in the preglomerular arterioles even in
cases with only minimal or mild glomerular involvement.
In contrast, some cases of AA amyloidosis with moderate or
severe glomerular involvement lacked deposits within the
arterioles and/or arteries. In all cases of AL amyloidosis with
a clinically reported monoclonal light chain, the specificity
of the light chain found by immunohistochemistry was the
same as the one found in the serum or urine.
The reported proteinuria at the time of biopsy was higher in
the patients presenting with the glomerular type compared to
the vascular type (Figure 5A). There was no significant differ-
ence compared to the interstitial type. Within the glomerular
type, proteinuria significantly increased with diffuse involve-
ment of the glomeruli (Figure 5B; median: focal segmental 5 g/
day, diffuse segmental and diffuse global early 7 g/day and
diffuse global late 9 g/day; Kruskal–Wallis test: P < 0.05).
Patients with the vascular type tended to present with a
higher serum creatinine (Figure 5C). However, this was not
significant. As expected, serum creatinine correlated with the
area% of interstitial fibrosis with tubular atrophy (Spear-
man’s r ¼ 0.6585, P < 0.0001; Figure 5D). In relation to
the pattern of glomerular amyloid deposition, creatinine was
significantly increased once amyloid was distributed in
a global fashion (Figure 5E; median: focal segmental
79 lmol/L, diffuse segmental 88 lmol/L, diffuse global
early 121 lmol/L and diffuse global late 257 lmol/L;
Kruskal–Wallis test: P < 0.0001).
Fig. 2. Dynamics of glomerular amyloid deposition (PAS, original magnification: 3400).
Fig. 3. Stages of glomerular amyloid deposition and involvement of other
compartments.
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Discussion
Identification of amyloid and establishment of its biochem-
ical type is the key information provided by the renal path-
ologists evaluating the patients’ kidney biopsies. Using a
systematic workup of standard histological sections and
stains, we aimed to identify additional parameters which
may be relevant to patient care, especially in the context of
the emerging new anti-fibrillar therapies.
Undisputedly, immunohistochemical typing is currently
the most important task in the workup of a renal biopsy
with amyloidosis because it determines the clinical man-
agement and therapy [2, 13]. It should be performed in all
cases. In the past, typing of AL amyloidosis using antisera
against lambda and kappa light chains has been a major
problem, often providing false-negative results [14–16].
We were fortunate to have amyloid-specific polyclonal sera
against lambda and kappa light chains (kindly provided by
Prof. R. Linke, Martinsried, Germany), which enabled us to
reliably type >97% of our cases. These antisera have re-
cently become commercially available. In the future, this
will tremendously help pathologists typing AL amyloido-
sis, especially on paraffin sections. Our study also shows
that as a first-step antisera against AA, AL lambda and AL
kappa are sufficient to type the majority of cases.
Although the three amyloid distribution patterns have
been described in the literature, they are frequently not
mentioned in renal pathology textbooks and probably not
reported by many pathologists [5, 6, 9]. It is hard to believe
that the distribution patterns within the renal compartments
occur by mere chance. Both AL and AA may be domi-
nantly deposited in any of the renal compartments, imply-
ing that these proteins are not a homogenous chemical
entity. In recent years, much progress has been made in
the understanding of the pathogenesis of amyloidosis
[17–21]. The precise mechanism of amyloid deposition is
not completely understood. However, once fibrils have
been seeded, there is a strong tendency for further self-
aggregation. In addition to the deposited fibrils, unstable
precursor molecules may have a toxic effect resulting in
further organ dysfunction [1]. Much evidence suggests
that the chemicophysical properties of the amyloid
fibrils determine their tropism in regard to which organs
and also which compartments are affected [12, 22]. The
chemicophysical properties in an individual case depend on
the biochemical type, the amino acid sequence, especially
in cases with mutations (AL, hereditary amyloidosis), and
Fig. 4. Glomerular obsolescence (A) and amount of interstitial fibrosis
with tubular atrophy (IFTA) (B) in different stages of glomerular amyloid
deposition. Kruskal–Wallis test P <0.0001 for both A and B. Box plots
show 25th, 50th and 75th percentile and the whiskers show the 5th and
95th percentile. fs, focal segmental; ds, diffuse segmental; dg, diffuse
global. Levels of significance: **P < 0.01 and ***P < 0.001. (C) Per-
centage of cases with glomerular, vascular and interstitial distribution
types in AA and AL amyloidosis. Glomerular type is further subdivided
by stage.
Fig. 5. Correlation of morphological parameters with clinical data provided
at the time of kidney biopsy. (A) Proteinuria plotted against amyloid distri-
bution type. Kruskal–Wallis test, P < 0.0001. (B) Proteinuria plotted against
glomerular stages. Kruskal–Wallis test, P < 0.05. (C) Serum creatinine plot-
ted against amyloid distribution types. Kruskal–Wallis test, P ¼ not signifi-
cant. (D) Correlation between serum creatinine and interstitial fibrosis with
tubular atrophy (IFTA). Spearman’s r ¼ 0.6585, P < 0.0001. (E) Serum
creatinine plotted against glomerular stages. Kruskal–Wallis test, P <
0.0001. (A–C and E) Box plots show 25th, 50th and 75th percentile, the
whiskers show the 5th and 95th percentile. fs, focal segmental; ds, diffuse
segmental; dg, diffuse global. Levels of significance: *P < 0.05, **P < 0.01
and ***P < 0.001.
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proteolytic cleavage resulting in protein fragments of var-
ious sizes [10, 23, 24]. The latter has been described for
both AA and ATTR proteins [10, 12]. Currently, the dis-
tribution patterns have only limited clinical meaning. This
may change, once correlations have been established be-
tween certain chemicophysical properties and deposition
patterns.
The glomerular pattern of amyloid deposition is most
common, comprising >80% of the cases. Although glo-
merular amyloid deposition is clearly a continuous proc-
ess, it can be arbitrarily divided into three stages: (I) focal
segmental, (II) diffuse segmental and (III) diffuse global
glomerular involvement. Stage III can be further divided
into an early and a late phase. The stages correlate both
with clinical as well as pathological parameters, making
this staging useful and meaningful. Proteinuria is the clin-
ical hallmark feature of glomerular amyloidosis, even in
the early stage [9]. Proteinuria significantly increases with
progression from a focal (I) to a diffuse (II and III) glo-
merular deposition. This is also true for the glomerular
amyloid deposits in the vascular and interstitial distribu-
tion patterns. In contrast, a significant rise in serum crea-
tinine was seen in the transition from segmental (I and II)
to global lesions (III) with a further increase in the late
global stage. This is most likely due to the secondary
interstitial fibrosis and tubular atrophy, which shows a
strong correlation with the glomerular stages. The high
correlation between serum creatinine and interstitial fib-
rosis, which was also found in this study, is well known
and has already been shown for renal amyloidosis >20
years ago [4, 9, 25]. In both AL and AA amyloidosis, the
majority of patients are diagnosed in Stage III. It is im-
portant to point out that these later stages have increasing
chronic lesions (glomerular obsolescence, tubular atrophy
and interstitial fibrosis), which may not be accessible to
anti-amyloid therapy. Our series contained only few cases
with other glomerular patterns such as the nodular type
[26] and there was no correlation with the biochemical
amyloid type.
Recently, Sen and Sarsik [27] proposed a histopathologic
classification, scoring and grading system for renal amyloi-
dosis similar to the classification of systemic lupus erythe-
matodes. The staging system used by us is similar in several
ways but in our opinion much easier to use in the setting of
daily routine diagnostics. In addition, we show clear corre-
lations with pathological features (glomerular obsolescence
and interstitial fibrosis with tubular atrophy) and laboratory
parameters (proteinuria and serum creatinine).
Depending on the stage, we noticed an increasingly less
conspicuous involvement of preglomerular arterioles, inter-
lobular arteries and the interstitium. It is not clear whether
this reflects an ‘overflow’ mechanism or is due to a differ-
ent fibril composition.
The vascular pattern is characterized by dominant amy-
loid deposits within arteries and arterioles. The deposition
within the blood vessels was quite heterogenous in regard
to segmental or circular deposits and also intima or media
involvement. A number of previous studies have de-
scribed the vascular in comparison to the glomerular form
[5–9]. The frequency of the vascular distribution pattern
varied between 12.5 and 39%, and it was 9.4% in our
series. As in the other studies, proteinuria in the vascular
pattern was lower. It is believed that the vascular pattern
frequently presents with renal insufficiency. In this regard,
our data showed only a nonsignificant trend. This may be
due to the high number of glomerular cases diagnosed late
in the course of the disease.
The interstitial pattern accounts for only 5.9% of our
cases. Amyloid deposits either surround the tubules and
peritubular capillaries of the cortex or may predominantly
affect the blood vessels along the vasa recta. In renal biop-
sies, it is difficult to tell the distribution within medulla and
cortex, but the amyloid deposits may be limited to the me-
dulla [5, 28]. Some of the cases documented in the literature
have presented as diabetes insipidus renalis [29, 30]. None of
our cases showed this presentation.
Our series contains only one case with a hereditary amy-
loidosis and we did not identify cases with other infrequent
amyloid types. We have not tested for the newly described
leukocyte cell-derived chemotoxin 2 protein [31, 32].
Therefore, we cannot tell whether these infrequent amyloid
types show any preferential deposition patterns.
Several drugs are being developed that target the forma-
tion and stability of amyloid fibrils or the conversion of
precursor proteins to folding intermediates [33–36] that will
likely change amyloidosis treatment. It is well conceivable
that not only the formation of new renal amyloid deposits
will be blocked but also that existing amyloid deposits may
be degraded. Looking at the distribution of amyloid within
the renal compartments and particularly the stage of glomer-
ular deposition, one would expect that the late stages, IIIa
and, especially, IIIb, may not respond very well to anti-
fibrillar therapy due to the chronic glomerular and tubuloin-
terstitial lesions. One will also have to consider what will
happen to the advanced glomerular or vascular lesions once
the amyloid is taken away, especially if the resident cells
have mostly disappeared. We believe that it is likely that
eventually some type of scar (i.e. glomerular and/or vascular
sclerosis) will evolve. We therefore think that in the future,
the amyloid distribution pattern, the glomerular stage and the
amount of interstitial fibrosis with tubular atrophy will be-
come important parameters for clinical decision making in
patients with renal amyloidosis.
In summary, our findings show three easily recogniz-
able distribution patterns of amyloid deposition in the
kidney. These do not correlate with the biochemical type
but may become relevant for future correlations with
physicochemical properties of amyloid and anti-fibrillar
therapies. Staging amyloidosis and providing a good es-
timate of the amount of interstitial fibrosis with tubular
atrophy may be useful to predict the efficacy of an anti-
fibrillar treatment.
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